RÉSUMÉ
BACKGROUND: Patients living with life-limiting illnesses other than cancer constitute the majority of patients in need of palliative care globally, yet most previous systematic reviews of the cost impact of palliative care have not exclusively focused on this population. Reviews that tangentially looked at non-cancer patients found inconclusive evidence. Randomised controlled trials (RCTs) are the gold standard for treatment efficacy, while total health care costs offer a comprehensive measure of resource use. In the sole review of RCTs for non-cancer patients, palliative care reduced hospitalisations and emergency department visits but its effect on total health care costs was not assessed. The aim of this study is to review RCTs to determine the difference in costs between a palliative care approach and usual care in adult non-cancer patients with a life-limiting illness. METHODS: A systematic review using a narrative synthesis approach. The protocol was registered with PROSPERO prospectively (no. CRD42020191082). Eight databases were searched: Medline, CINAHL, EconLit, EMBASE, TRIP database, NHS Evidence, Cochrane Library, and Web of Science from inception to January 2023. Inclusion criteria were: English or German; randomised controlled trials (RCTs); adult non-cancer patients (> 18 years); palliative care provision; a comparator group of standard or usual care. Quality of studies was assessed using Drummond's checklist for assessing economic evaluations. RESULTS: Seven RCTs were included and examined the following diseases: neurological (3), heart failure (2), AIDS (1) and mixed (1). The majority (6/7) were home-based interventions. All studies were either cost-saving (3/7) or cost-neutral (4/7); and four had improved outcomes for patients or carers and three no change in outcomes. CONCLUSIONS: In a non-cancer population, this is the first systematic review of RCTs that has demonstrated a palliative care approach is cost-saving or at least cost-neutral. Cost savings are achieved without worsening outcomes for patients and carers. These findings lend support to calls to increase palliative care provision globally.
Sujet(s)
Soins palliatifs , Essais contrôlés randomisés comme sujet , Humains , Soins palliatifs/économie , Soins palliatifs/méthodes , Soins palliatifs/normes , Adulte , Économies/méthodes , Économies/statistiques et données numériques , Analyse coût-bénéfice/méthodesRÉSUMÉ
Pharmacist-led interventions are pivotal in identifying and resolving potential adverse drug events (pADEs) while enhancing blood pressure control and medication adherence through educational and counseling interventions. This practice brief outlines the outcomes of the Blue Bag Initiative (BBI), which enhanced pharmacist-led comprehensive medication reviews (CMRs) across community pharmacies in Virginia under Center for Disease Control Cooperative Agreement NU58DP006535. BBI yielded a rate of 131.6 pADEs identified per 100 participants and demonstrated cost savings of 1 to 3 million dollars for the health care system. This report underscores the significance of a standardized, pharmacist-led CMR as integral to interdisciplinary team-based care models within physician practices, facilitating medication therapy management implementation. Enhanced CMR can improve cardiovascular health outcomes while reducing health care expenditures by augmenting patient engagement and medication adherence. This study thus highlights the efficacy and potential of pharmacist-led interventions in increasing access to and optimizing patient care.
Sujet(s)
Économies , Participation des patients , Humains , Économies/méthodes , Économies/statistiques et données numériques , Participation des patients/méthodes , Participation des patients/statistiques et données numériques , Virginie , Pharmaciens/statistiques et données numériques , Adhésion au traitement médicamenteux/statistiques et données numériques , Effets secondaires indésirables des médicaments/prévention et contrôle , Gestion de la pharmacothérapie/économieSujet(s)
Acné juvénile , Antibactériens , Économies , Types de pratiques des médecins , Humains , Acné juvénile/traitement médicamenteux , Acné juvénile/économie , Adolescent , Antibactériens/économie , Antibactériens/administration et posologie , Antibactériens/usage thérapeutique , Administration par voie orale , Études rétrospectives , Économies/statistiques et données numériques , Types de pratiques des médecins/statistiques et données numériques , Types de pratiques des médecins/économie , Mâle , Femelle , Durée du traitement , Calendrier d'administration des médicamentsRÉSUMÉ
OBJECTIVE: To assess the outcomes, total healthcare utilization, and cost savings for same-day discharge (SDD) vs inpatient robotic-assisted partial nephrectomy (RAPN) and robotic-assisted radical nephrectomy (RARN). METHODS: We compared 146 RAPNs and 65 RARNs consecutively performed as SDD (RAPN=21, RARN=9) vs inpatient (RAPN=125, RARN=56) from April 2015 to May 2023 at two academic medical centers. We collected baseline demographics, perioperative characteristics, and 30-day complications. We applied the Time-Driven Activity-Based Costing analysis to compare total costs of RAPN and PARN throughout the cycle of care, including inpatient vs SDD. RESULTS: Baseline demographics and comorbidities were similar between patients undergoing inpatient vs SDD RAPN and RARN. One Clavien-Dindo grade II complication (3.3%) requiring readmission due to wound infection for antibiotics occurred after SDD RAPN; no complications occurred after SDD RARN. Two unscheduled office or emergency department visits (6.7%) occurred after SDD RAPN for surgical-site infection and urinary retention. SDD vs inpatient RAPN and RARN demonstrated a $3091 (18%) and $4003 (25%) overall cost reduction, respectively. CONCLUSION: SDD RAPN and RARN result in cost savings of 18%-25% without a difference in complications, and thereby improves value-based care for appropriately selected patients.
Sujet(s)
Tumeurs du rein , Néphrectomie , Sortie du patient , Interventions chirurgicales robotisées , Humains , Néphrectomie/économie , Néphrectomie/méthodes , Néphrectomie/effets indésirables , Interventions chirurgicales robotisées/économie , Interventions chirurgicales robotisées/effets indésirables , Mâle , Femelle , Adulte d'âge moyen , Tumeurs du rein/chirurgie , Tumeurs du rein/économie , Sortie du patient/statistiques et données numériques , Sujet âgé , Études rétrospectives , Économies/statistiques et données numériques , Facteurs temps , Hospitalisation/économie , Hospitalisation/statistiques et données numériques , Résultat thérapeutique , Complications postopératoires/épidémiologie , Complications postopératoires/économie , Complications postopératoires/étiologie , Patients hospitalisés/statistiques et données numériquesRÉSUMÉ
BACKGROUND: Mohs micrographic surgery efficiently treats skin cancer through staged resection, but surgeons' varying resection rates may lead to higher medical costs. OBJECTIVE: To evaluate the cost savings associated with a quality improvement. MATERIALS AND METHODS: The authors conducted a retrospective cohort study using 100% Medicare fee-for-service claims data to identify the change of mean stages per case for head/neck (HN) and trunk/extremity (TE) lesions before and after the quality improvement intervention from 2016 to 2021. They evaluated surgeon-level change in mean stages per case between the intervention and control groups, as well as the cost savings to Medicare over the same time period. RESULTS: A total of 2,014 surgeons performed Mohs procedures on HN lesions. Among outlier surgeons who were notified, 31 surgeons (94%) for HN and 24 surgeons (89%) for TE reduced their mean stages per case with a median reduction of 0.16 and 0.21 stages, respectively. Reductions were also observed among outlier surgeons who were not notified, reducing their mean stages per case by 0.1 and 0.15 stages, respectively. The associated total 5-year savings after the intervention was 92 million USD. CONCLUSION: The implementation of this physician-led benchmarking model was associated with broad reductions of physician utilization and significant cost savings.
Sujet(s)
Économies , Medicare (USA) , Chirurgie de Mohs , Amélioration de la qualité , Tumeurs cutanées , Humains , Études rétrospectives , Medicare (USA)/économie , États-Unis , Amélioration de la qualité/économie , Économies/statistiques et données numériques , Tumeurs cutanées/chirurgie , Tumeurs cutanées/économie , Chirurgie de Mohs/économie , Études de suivi , Types de pratiques des médecins/économie , Types de pratiques des médecins/statistiques et données numériques , Mâle , Femelle , Chirurgiens/économie , Chirurgiens/statistiques et données numériques , Tumeurs de la tête et du cou/chirurgie , Tumeurs de la tête et du cou/économieRÉSUMÉ
INTRODUCTION: Approximately 75% of traumatic brain injuries (TBIs) qualify as mild. However, there exists no universally agreed upon definition for mild TBI (mTBI). Consequently, treatment guidelines for this group are lacking. The Center for Disease Control (CDC), American College of Rehabilitation Medicine (ACRM), Veterans Affairs and Department of Defense (VA/DoD), Eastern Association for the Surgery of Trauma (EAST), and the University of Arizona's Brain Injury Guidelines (BIG) have each published differing definitions for mTBI. The aim of this study was to compare the ability of these definitions to correctly classify mTBI patients in the acute care setting. METHODS: A single-center, retrospective cohort study comparing the performance of the varying definitions of mTBI was performed at a Level I trauma center from August 2015 to December 2018. Definitions were compared by sensitivity, specificity, positive predictive value, negative predictive value, as well as overtriage and undertriage rates. Finally, a cost-savings analysis was performed. RESULTS: We identified 596 patients suffering blunt TBI with Glasgow Coma Scale 13-15. The CDC/ACRM definitions demonstrated 100% sensitivity but 0% specificity along with the highest rate of undertriage and TBI-related mortality. BIG 1 included nearly twice as many patients than EAST and VA/DoD while achieving a superior positive predictive value and undertriage rate. CONCLUSIONS: The BIG definition identified a larger number of patients compared to the VA/DoD and EAST definitions while having an acceptable and more accurate overtriage and undertriage rate compared to the CDC and ACRM. By eliminating undertriage and minimizing overtriage rates, the BIG maintains patient safety while enhancing the efficiency of healthcare systems. Using the BIG definition, a cost savings of $395,288.95-$401,263.95 per year could be obtained at our level 1 trauma facility without additional mortality.
Sujet(s)
Commotion de l'encéphale , Humains , Études rétrospectives , Femelle , Mâle , Adulte d'âge moyen , Commotion de l'encéphale/diagnostic , Commotion de l'encéphale/thérapie , Adulte , Sujet âgé , Triage/normes , Triage/méthodes , Guides de bonnes pratiques cliniques comme sujet , Centres de traumatologie/statistiques et données numériques , Sensibilité et spécificité , Jeune adulte , Économies/statistiques et données numériques , Échelle de coma de GlasgowRÉSUMÉ
BACKGROUND: Tailoring asthma interventions based on biomarkers could substantially impact the high cost associated with asthma morbidity. For policymakers, the main concern is the economic impact of adopting this technology, especially in developing countries. This study evaluates the budget impact of asthma management using sputum eosinophil counts in Colombia patients between 4 and 18 years of age. METHODS: A budget impact analysis was performed to evaluate the potential financial impact of sputum eosinophil counts (EO). The study considered a 5-year time horizon and the Colombian National Health System perspective. The incremental budget impact was calculated by subtracting the cost of the new treatment, in which EO is reimbursed, from the cost of the conventional therapy without EO (management based on clinical symptoms (with or without spirometry/peak flow) or asthma guidelines (or both), for asthma-related). Univariate one-way sensitivity analyses were performed. RESULTS: In the base-case analysis, the 5-year costs associated with EO and no-EO were estimated to be US$ 532.865.915 and US$ 540.765.560, respectively, indicating savings for Colombian National Health equal to US$ 7.899.645, if EO is adopted for the routine management of patients with persistent asthma. This result was robust in univariate sensitivity one-way analysis. CONCLUSION: EO was cost-saving in guiding the treatment of patients between 4 and 18 years of age with persistent asthma. Decision-makers in our country can use this evidence to improve clinical practice guidelines, and it should be replicated to validate their results in other middle-income countries.
Sujet(s)
Asthme , Granulocytes éosinophiles , Guides de bonnes pratiques cliniques comme sujet , Expectoration , Humains , Asthme/économie , Asthme/thérapie , Enfant , Adolescent , Colombie , Enfant d'âge préscolaire , Expectoration/cytologie , Numération des leucocytes , Femelle , Mâle , Économies/statistiques et données numériques , Pays en voie de développementRÉSUMÉ
Aim: To estimate cost-savings from conversion to biosimilar pegfilgrastim-cbqv that could be reallocated to provide budget-neutral expanded access to AC (doxorubicin/cyclophosphamide) and TCH (docetaxel/carboplatin/trastuzumab) in breast cancer (BC) patients. Methods: Simulation modeling in panels of 20,000 BC and 5000 HER2+ (HER2+ BC) patients, varying treatment duration (one-six cycles) and conversion rates (10-100%), to estimate cost-savings and additional AC and TCH treatment that could be provided. Results: In 20,000 patients, cost-savings of $1,083 per-patient per-cycle translate to $21,652,064 (one cycle) to $129,912,397 (six cycles). Savings range from $5,413,016 to $32,478,097, respectively, in the 5000-patient HER2+ BC panel. Conclusion: Conversion to pegfilgrastim-cbqv could save up to $130 million and provide more than 220,000 additional cycles of antineoplastic treatment on a budget-neutral basis to BC patients.
Lay abstract Pegfilgrastim is used to prevent low white blood cell count in patients receiving chemotherapy. Comparable to a generic version of a drug, a biosimilar is a follow-on version of a biologic treatment. We calculated the savings from using biosimilar pegfilgrastim in a hypothetical group of 20,000 patients with breast cancer receiving chemotherapy with AC (doxorubicin/cyclophosphamide). We then computed the number of additional doses of AC chemotherapy that could be purchased with those savings. We did the same for a group of 5000 HER2+ breast cancer patients treated with TCH (docetaxel/carboplatin/trastuzumab). Using biosimilar pegfilgrastim could save $1,083 per patient per cycle. If all patients were treated with biosimilar pegfilgrastim over six cycles, $129.9 million could be saved in the AC group and $32.5 million in the TCH group. This could provide 220,468 additional AC doses and 6981 TCH doses. Biosimilar pegfilgrastim can generate significant savings. These savings can be used to provide additional patients with chemotherapy cost-free.
Sujet(s)
Produits pharmaceutiques biosimilaires/usage thérapeutique , Tumeurs du sein/traitement médicamenteux , Économies/statistiques et données numériques , Filgrastim/usage thérapeutique , Accessibilité des services de santé/statistiques et données numériques , Polyéthylène glycols/usage thérapeutique , Sujet âgé , Produits pharmaceutiques biosimilaires/économie , Tumeurs du sein/économie , Simulation numérique , Coûts des médicaments , Substitution de médicament/économie , Substitution de médicament/statistiques et données numériques , Femelle , Filgrastim/économie , Humains , Medicare (USA)/économie , Medicare (USA)/statistiques et données numériques , Adulte d'âge moyen , Modèles économiques , Polyéthylène glycols/économie , États-UnisRÉSUMÉ
PURPOSE: We aim to assess the healthcare value achieved from a shared savings program for pediatric appendectomy. METHODS: All appendectomy patients covered by our health plan were included. Quality targets were 15% reduction in time to surgery, length of stay, readmission rate, and patient satisfaction. Quality targets and costs for an appendectomy episode in two 6-month performance periods (PP1, PP2) were compared to baseline. RESULTS: 640 patients were included (baseline:317, PP1:167, PP2:156). No quality targets were met in PP1. Two quality targets were met during PP2: readmission rate (-57%) and patient satisfaction. No savings were realized because the cost reduction threshold (-9%) was not met during PP1 (+1.7%) or PP2 (-0.4%). CONCLUSIONS: Payer-provider partnerships can be a platform for testing value-based reimbursement models. Setting achievable targets, identifying affectable quality metrics, considering case mix index, and allowing sufficient time for interventions to generate cost savings should be considered in future programs.
Sujet(s)
Appendicectomie/économie , Appendicite/chirurgie , Économies/statistiques et données numériques , Assurance basée sur la valeur/économie , Adolescent , Appendicectomie/statistiques et données numériques , Appendicite/économie , Enfant , Enfant d'âge préscolaire , Groupes homogènes de malades/économie , Groupes homogènes de malades/statistiques et données numériques , Humains , Nourrisson , Nouveau-né , Mâle , Réadmission du patient/économie , Réadmission du patient/statistiques et données numériques , Projets pilotes , Assurance basée sur la valeur/statistiques et données numériquesRÉSUMÉ
OBJECTIVE: Many employers have introduced rewards programs as a new benefit design in which employees are paid $25-$500 if they receive care from lower-priced providers. Our goal was to assess the impact of the rewards program on procedure prices and choice of provider and how these outcomes vary by length of exposure to the program and patient population. STUDY SETTING: A total of 87 employers from across the nation with 563,000 employees and dependents who have introduced the rewards program in 2017 and 2018. STUDY DESIGN: Difference-in-difference analysis comparing changes in average prices and market share of lower-priced providers among employers who introduced the reward program to those that did not. DATA COLLECTION METHODS: We used claims data for 3.9 million enrollees of a large health plan. PRINCIPAL FINDINGS: Introduction of the program was associated with a 1.3% reduction in prices during the first year and a 3.7% reduction in the second year of access. Use of the program and price reductions are concentrated among magnetic resonance imaging (MRI) services, for which 30% of patients engaged with the program, 5.6% of patients received an incentive payment in the first year, and 7.8% received an incentive payment in the second year. MRI prices were 3.7% and 6.5% lower in the first and second years, respectively. We did not observe differential impacts related to enrollment in a consumer-directed health plan or the degree of market-level price variation. We also did not observe a change in utilization. CONCLUSIONS: The introduction of financial incentives to reward patients from receiving care from lower-priced providers is associated with modest price reductions, and savings are concentrated among MRI services.
Sujet(s)
Participation aux coûts/économie , Régimes d'assurance maladie des salariés/économie , Motivation , Participation des patients/statistiques et données numériques , Préférence des patients/statistiques et données numériques , Adulte , Économies/statistiques et données numériques , Participation aux coûts/statistiques et données numériques , Régimes d'assurance maladie des salariés/statistiques et données numériques , Humains , Mâle , Politique organisationnelleRÉSUMÉ
BACKGROUND: Guidelines recommend screening for primary aldosteronism in patients diagnosed with hypertension and obstructive sleep apnea. Recent studies have shown that adherence to these recommendations is extremely low. It has been suggested that cost is a barrier to implementation. No analysis has been done to rigorously evaluate the cost-effectiveness of widespread implementation of these guidelines. METHODS: We constructed a decision-analytic model to evaluate screening of the hypertensive obstructive sleep apnea population for primary aldosteronism as per guideline recommendations in comparison with current rates of screening. Probabilities, utility values, and costs were identified in the literature. Threshold and sensitivity analyses assessed robustness of the model. Costs were represented in 2020 US dollars and health outcomes in quality-adjusted life-years. The model assumed a societal perspective with a lifetime time horizon. RESULTS: Screening per guideline recommendations had an expected cost of $47,016 and 35.27 quality-adjusted life-years. Continuing at current rates of screening had an expected cost of $48,350 and 34.86 quality-adjusted life-years. Screening was dominant, as it was both less costly and more effective. These results were robust to sensitivity analysis of disease prevalence, test sensitivity, patient age, and expected outcome of medical or surgical treatment of primary aldosteronism. The screening strategy remained cost-effective even if screening were conservatively presumed to identify only 3% of new primary aldosteronism cases. CONCLUSIONS: For patients with hypertension and obstructive sleep apnea, rigorous screening for primary aldosteronism is cost-saving due to cardiovascular risk averted. Cost should not be a barrier to improving primary aldosteronism screening adherence.
Sujet(s)
Économies/statistiques et données numériques , Hyperaldostéronisme/diagnostic , Hypertension artérielle/étiologie , Dépistage de masse/économie , Syndrome d'apnées obstructives du sommeil/étiologie , Adulte , Sujet âgé , Analyse coût-bénéfice , Femelle , Humains , Hyperaldostéronisme/complications , Hyperaldostéronisme/économie , Hyperaldostéronisme/thérapie , Hypertension artérielle/économie , Hypertension artérielle/thérapie , Mâle , Chaines de Markov , Dépistage de masse/normes , Adulte d'âge moyen , Modèles économiques , Guides de bonnes pratiques cliniques comme sujet , Années de vie ajustées sur la qualité , Syndrome d'apnées obstructives du sommeil/économie , Syndrome d'apnées obstructives du sommeil/thérapieRÉSUMÉ
OBJECTIVES: Perioperative inefficiency can increase cost. We describe a process improvement initiative that addressed preoperative delays on an academic vascular surgery service. METHODS: First case vascular surgeries from July 2019-January 2020 were retrospectively reviewed for delays, defined as late arrival to the operating room (OR). A stakeholder group spearheaded by a surgeon-informaticist analyzed this process and implemented a novel electronic medical records (EMR) preoperative tool with improved preoperative workflow and role delegation; results were reviewed for 3 months after implementation. RESULTS: 57% of cases had first case on-time starts with average delay of 19 min. Inappropriate preoperative orders were identified as a dominant delay source (average delay = 38 min). Three months post-implementation, 53% of first cases had on-time starts with average delay of 11 min (P < 0.05). No delays were due to missing orders. CONCLUSIONS: Inconsistent preoperative workflows led to inappropriate orders and delays, increasing cost and decreasing quality. A novel EMR tool subsequently reduced delays with projected savings of $1,200/case. Workflow standardization utilizing informatics can increase efficiency, raising the value of surgical care.
Sujet(s)
Économies/statistiques et données numériques , Efficacité fonctionnement/économie , Informatique médicale , Blocs opératoires/organisation et administration , Procédures de chirurgie vasculaire/organisation et administration , Centres hospitaliers universitaires/économie , Centres hospitaliers universitaires/organisation et administration , Centres hospitaliers universitaires/statistiques et données numériques , Efficacité fonctionnement/normes , Efficacité fonctionnement/statistiques et données numériques , Mise en oeuvre des programmes de santé/organisation et administration , Mise en oeuvre des programmes de santé/statistiques et données numériques , Humains , Blocs opératoires/économie , Blocs opératoires/normes , Blocs opératoires/statistiques et données numériques , Guides de bonnes pratiques cliniques comme sujet , Évaluation de programme , Amélioration de la qualité , Études rétrospectives , Analyse de cause racine/statistiques et données numériques , Procédures de chirurgie vasculaire/économie , Procédures de chirurgie vasculaire/statistiques et données numériques , Flux de travauxRÉSUMÉ
OBJECTIVE: Compassionate Drug Use (CDU) allows patients with a specific disease and no further treatment option to access unauthorized treatments. In this study, we analyzed the requests of CDU approved by the Ethics Committee of Fondazione Policlinico Gemelli in the period January 1, 2018-June 30, 2021. We also estimated the economic impact of CUs. MATERIALS AND METHODS: CDU requests were analyzed by year, by frequency and by regulatory status of the medicines requested. If an ex-factory price was available at the cutoff date of June 30, 2021, we estimated what would have been the costs for the National Health System (NHS) if the price was already negotiated at the time of CDU request. RESULTS: In the study period, 463 CDU requests were processed by the Ethics Committee. The number of requests increase linearly from 45 in 2018 to an estimated number of 260 in 2021. The requests included 68 medicines or combinations of medicines; 16 products out of 68 accounted for 75% of all requests. For 7 of these 16 highly requested treatments, accounting for 110 requests out of 463, it was possible to estimate the costs of therapies according to their ex-factory prices. If these products were to be purchased by the NHS, the estimated cost was 5.472.225. CONCLUSIONS: The access to unauthorized drugs through CDUs is undergoing a huge increase in the last few years. Such increase meets the ethical need to provide patients with the most recent, often innovative, therapeutic options.
Sujet(s)
Essais cliniques à usage compassionnel/statistiques et données numériques , Prestations des soins de santé/statistiques et données numériques , Coûts des soins de santé/statistiques et données numériques , Programmes nationaux de santé/statistiques et données numériques , Essais cliniques à usage compassionnel/économie , Essais cliniques à usage compassionnel/tendances , Économies/statistiques et données numériques , Prestations des soins de santé/économie , Humains , Italie , Programmes nationaux de santé/économieRÉSUMÉ
Whole grain consumption has been associated with the reduced risk of several chronic diseases with significant healthcare monetary burden, including cancer. Colorectal cancer (CRC) is one of the most common cancers globally, with the highest rates reported in Australia. Three servings of whole grains provide a 15% reduction in total cancer and 17% reduction in CRC risk; however, 70% of Australians fall short of this level of intake. The aim of this study was to assess the potential savings in healthcare costs associated with reductions in the relative risk of CRC and total cancer mortality following the whole grain Daily Target Intake (DTI) of 48 g in Australia. A three-step cost-of-illness analysis was conducted using input parameters from: (1) estimates of current and targeted whole grain intakes among proportions (5%, 15%, 50%, and 100%) of the Australian adult (≥20 years) population; (2) estimates of reductions in relative risk (with 95% confidence intervals) of CRC and total cancer mortality associated with specific whole grain intake from meta-analysis studies; and (3) estimates of annual healthcare costs of CRC and all cancers from disease expenditure national databases. A very pessimistic (5% of population) through to universal (100% of population) adoption of the recommended DTI in Australia were shown to potentially yield savings in annual healthcare costs equal to AUD 1.9 (95% CI 1.2-2.4) to AUD 37.2 (95% CI 24.1-48.1) million for CRC and AUD 20.3 (95% CI 12.2-27.0) to AUD 405.1 (95% CI 243.1-540.1) million for total cancers. As treatment costs for CRC and other cancers are increasing, and dietary measures exchanging whole grains for refined grains are not cost preclusive nor does the approach increase energy intake, there is an opportunity to facilitate cost-savings along with reductions in disease for Australia. These results suggest specific benefits of encouraging Australians to swap refined grains for whole grains, with greater overall adherence to suggestions in dietary guidelines.
Sujet(s)
Économies/statistiques et données numériques , Régime alimentaire/méthodes , Coûts des soins de santé/statistiques et données numériques , Tumeurs/prévention et contrôle , Grains complets , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Australie , Enfant , Enfant d'âge préscolaire , Tumeurs colorectales/économie , Tumeurs colorectales/prévention et contrôle , Économies/économie , Analyse coût-bénéfice/économie , Analyse coût-bénéfice/méthodes , Analyse coût-bénéfice/statistiques et données numériques , Femelle , Humains , Mâle , Adulte d'âge moyen , Tumeurs/économie , Jeune adulteRÉSUMÉ
BACKGROUND: Health-care expenditures in the U.S. are continually rising, prompting providers, patients, and payers to search for solutions to reduce costs while maintaining quality. The present study seeks to define the out-of-pocket price that patients undergoing hand surgery are willing to pay, and also queries the potential cost-cutting measures that patients are most and least comfortable with. We hypothesized that respondents would be less accepting of higher out-of-pocket costs. METHODS: A survey was developed and distributed to paid, anonymous respondents through Amazon Mechanical Turk. The survey introduced 3 procedures: carpal tunnel release, cubital tunnel release, and open reduction and internal fixation of a distal radial fracture. Respondents were randomized to 1 of 5 out-of-pocket price options for each procedure and asked if they would pay that price. Respondents were then presented with various cost-saving methods and asked to select the options that made them most uncomfortable, even if those would save them out-of-pocket costs. RESULTS: There were 1,408 respondents with a mean age of 37 years (range, 18 to 74 years). Nearly 80% of respondents were willing to pay for all 3 of the procedures regardless of which price they were presented. Carpal tunnel release was the most price-sensitive, with rejection rates of 17% at the highest price ($3,000) and 6% at the lowest ($250). Open reduction and internal fixation was the least price-sensitive, with rejection rates of 11% and 6% at the highest and lowest price, respectively. The use of older-generation implants was the least acceptable cost-cutting measure, at 50% of respondents. CONCLUSIONS: The present study showed that most patients are willing to pay a considerable amount of money out of pocket for hand surgery after the condition, treatment, and outcomes are explained to them. Furthermore, respondents are hesitant to sacrifice advanced technology despite increased costs.
Sujet(s)
Comportement du consommateur/statistiques et données numériques , Main/chirurgie , Dépenses de santé/statistiques et données numériques , Procédures orthopédiques/économie , Adolescent , Adulte , Sujet âgé , Comportement du consommateur/économie , Économies/méthodes , Économies/statistiques et données numériques , Femelle , Humains , Mâle , Adulte d'âge moyen , Procédures orthopédiques/méthodes , Enquêtes et questionnaires/statistiques et données numériques , Jeune adulteRÉSUMÉ
Aim: To estimate the cost-savings from conversion to biosimilar pegfilgrastim-cbqv that can be reallocated to provide budget-neutral expanded access to FOLFIRINOX in patients with metastatic pancreatic cancer. Methods: Simulation modeling in a panel of 2500 FOLFIRINOX-treated patients, using varying treatment duration (1-12 cycles) and conversion rates (10-100%), to estimate cost-savings and additional FOLFIRINOX treatment that could be budget neutral. Results: In a 2500-patient panel at 100% conversion, savings of US$6,907.41 per converted patient over 12 cycles of prophylaxis translate to US$17.3 million and could provide 72,273 additional FOLFIRINOX doses or 6023 full 6-month regimens. Conclusion: Conversion to biosimilar CIN/FN prophylaxis can generate significant cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Lay abstract Pegfilgrastim is used to prevent low white blood cell count in patients receiving chemotherapy. Comparable to a generic version of a drug, a biosimilar is a follow-on version of a biologic treatment. The authors calculated the savings from using biosimilar pegfilgrastim in a hypothetical group of 2500 patients with metastatic pancreatic cancer and then computed the number of additional doses of FOLFIRINOX chemotherapy that could be purchased with those savings. Using biosimilar pegfilgrastim for 12 cycles could save US$6,907.41 per patient. If all 2500 patients were treated with biosimilar pegfilgrastim, US$17.3 million could be saved. This could provide 72,273 additional FOLFIRINOX doses. Biosimilar pegfilgrastim can generate significant savings to purchase chemotherapy for additional patients cost-free.
Sujet(s)
Protocoles de polychimiothérapie antinéoplasique/économie , Produits pharmaceutiques biosimilaires/économie , Filgrastim/économie , Tumeurs du pancréas/traitement médicamenteux , Polyéthylène glycols/économie , Sujet âgé , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Produits pharmaceutiques biosimilaires/usage thérapeutique , Simulation numérique , Économies/statistiques et données numériques , Analyse coût-bénéfice , Coûts des médicaments , Filgrastim/usage thérapeutique , Fluorouracil/économie , Fluorouracil/usage thérapeutique , Accessibilité des services de santé/économie , Accessibilité des services de santé/statistiques et données numériques , Humains , Irinotécan/économie , Irinotécan/usage thérapeutique , Leucovorine/économie , Leucovorine/usage thérapeutique , Adulte d'âge moyen , Modèles économiques , Oxaliplatine/économie , Oxaliplatine/usage thérapeutique , Tumeurs du pancréas/économie , Tumeurs du pancréas/anatomopathologie , Polyéthylène glycols/usage thérapeutique , Programme SEER/statistiques et données numériquesRÉSUMÉ
OBJECTIVES: The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding. METHODS: This cost-effectiveness analysis was performed as a long-term simulation using the Markov model from the Japanese public healthcare payer's perspective. The analysis was conducted using loxoprofen with real-world weighted price by branded/generic distribution (hereinafter, loxoprofen with weighted price) as a comparator. In the model, we simulated the prognosis of patients with chronic pain by OA, RA, and LBP treated with loxoprofen or celecoxib, over a lifetime period. RESULTS: A cost-increase of 129,688 JPY (1,245.00 USD) for branded celecoxib and a cost-reduction of 6,268 JPY (60.17 USD) for AG celecoxib were recognized per patient in lifetime horizon, compared to loxoprofen with weighted price. No case was recognized to reverse the results of cost-saving by AG celecoxib in one-way sensitivity analysis. The incremental cost-effectiveness ratio of branded celecoxib attained 5,403,667 JPY/QALY (51,875.20 USD/QALY), compared to loxoprofen with the weighted price. CONCLUSION: The current cost-effectiveness analysis for AG celecoxib revealed its good value for costs, considering the patients' future risk of gastrointestinal injury; also, the impact on costs due to AG celecoxib against loxoprofen will be small. It implies that the disadvantage of AG celecoxib being slightly more expensive than generic loxoprofen could be offset by the good cost-effectiveness during the prognosis.
Sujet(s)
Célécoxib/administration et posologie , Douleur chronique/traitement médicamenteux , Médicaments génériques/administration et posologie , Maladies gastro-intestinales/épidémiologie , Phénylpropionates/administration et posologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Célécoxib/effets indésirables , Célécoxib/économie , Douleur chronique/diagnostic , Simulation numérique , Économies/statistiques et données numériques , Analyse coût-bénéfice , Coûts des médicaments , Médicaments génériques/effets indésirables , Médicaments génériques/économie , Femelle , Maladies gastro-intestinales/induit chimiquement , Maladies gastro-intestinales/économie , Humains , Japon , Mâle , Chaines de Markov , Adulte d'âge moyen , Modèles économiques , Phénylpropionates/effets indésirables , Phénylpropionates/économie , Années de vie ajustées sur la qualité , Appréciation des risques/statistiques et données numériquesRÉSUMÉ
Cancer is one of the leading causes of death with 9.6 million deaths registered in 2018, of which 70% occur in Africa, Asia and Central and South America, the low-and middle-income countries (LMICs). The global annual expenditure on anticancer medicines increased from $96 billion in 2013 to $133 billion in 2017. This growth rate is several folds that of newly diagnosed cancer cases and therefore estimated to reach up to $200 billion by 2022. The Uganda Cancer Institute, Uganda's national referral cancer center, has increased access to cancer medicines through an efficient and cost-saving procurement system. The system has achieved cost savings of more than USD 2,000,000 on a total of 37 of 42 essential cancer medicines. This has resulted in 85.8% availability superseding the WHO's 80% target. All selected products were procured from manufacturers with stringent regulatory authority approval or a proven track record of quality products.
Sujet(s)
Antinéoplasiques/économie , Pays en voie de développement/économie , Médicaments essentiels/ressources et distribution , Accessibilité des services de santé/organisation et administration , Tumeurs/traitement médicamenteux , Antinéoplasiques/usage thérapeutique , Économies/méthodes , Économies/statistiques et données numériques , Coûts des médicaments/statistiques et données numériques , Médicaments essentiels/économie , Santé mondiale/statistiques et données numériques , Accessibilité des services de santé/économie , Humains , Tumeurs/économie , OugandaRÉSUMÉ
BACKGROUND: The aim was to describe the introduction and operation of a virtual developmental dysplasia of the hip (DDH) clinic. Our secondary objectives were to provide an overview of DDH referral reasons, treatment outcomes, and adverse events associated with it. METHODS: A prospective observational study involving all patients referred to the virtual DDH clinic was conducted. The clinic consultant delivered with 2 DDH clinical nurse specialists (CNS). The outcomes following virtual review include further virtual review, CNS review, consultant review or discharge. Treatment options include surveillance, brace therapy, or surgery. Efficiency and cost analysis were assessed. RESULTS: Over the 3.5-year study period, 1002 patients were reviewed, of which 743 (74.2%) were female. The median age at time of referral was 7 months, (interquartile range of 5 to 11) with a median time to treatment decision of 9 days. Median waiting times from referral to treatment decision was reduced by over 70%. There were 639 virtual reviews, 186 CNS reviews, and 144 consultant reviews. The direct discharge rate was 24%. One hundred one patients (10%) had dislocated or subluxed hips at initial visit while 26.3% had radiographically normal hips. Over the study period 704 face to face (F2F) visits were avoided. Cost reductions of 170 were achieved per patient, with 588,804 achieved in total. Eighteen parents (1.8%) opted for F2F instead of virtual review. There were no unscheduled rereferrals or recorded adverse events. CONCLUSION: We report the outcomes of the first prospective virtual DDH clinic. This clinic has demonstrated efficiency and cost-effectiveness, without reported adverse outcomes to date. It is an option to provide consultant delivered DDH care, while reducing F2F consults. LEVEL OF EVIDENCE: Level III.
Sujet(s)
Soins ambulatoires/méthodes , Luxation congénitale de la hanche/imagerie diagnostique , Luxation congénitale de la hanche/thérapie , Télémédecine/statistiques et données numériques , Soins ambulatoires/économie , Soins ambulatoires/organisation et administration , Orthèses de maintien , Économies/statistiques et données numériques , Femelle , Coûts des soins de santé/statistiques et données numériques , Humains , Nourrisson , Mâle , Infirmières spécialistes cliniques/organisation et administration , Consultation médicale/économie , Consultation médicale/statistiques et données numériques , Sortie du patient/statistiques et données numériques , Études prospectives , Orientation vers un spécialiste/statistiques et données numériques , Télémédecine/économie , Télémédecine/organisation et administration , Délai jusqu'au traitement , Résultat thérapeutique , Observation (surveillance clinique)RÉSUMÉ
BACKGROUND: Darolutamide, a structurally distinct androgen receptor inhibitor approved for the treatment of men with nonmetastatic castration-resistant prostate cancer (nmCRPC), has been shown to increase metastasis-free survival among men with nmCRPC compared with placebo. This treatment has a novel chemical structure that may also have safety, tolerability, and efficacy advantages for men with nmCRPC. OBJECTIVE: To estimate the projected budget impact of including darolutamide on a U.S. payer formulary as a treatment option for men with nmCRPC. METHODS: A budget impact model was developed to evaluate darolutamide for nmCRPC for a hypothetical 1-million-member plan over a 5-year period. Costs (drug acquisition, drug administration, and treatment-related adverse events [AEs]) were estimated for 2 scenarios: with and without darolutamide treatment for nmCRPC. The budget impact of darolutamide was calculated as the difference in costs for these 2 scenarios. An analysis for high-risk nmCRPC also was conducted. The model included treatments recommended by the National Comprehensive Cancer Network (e.g., apalutamide and enzalutamide) and potential comparators that are used but are not specifically indicated for nmCRPC. All treatments were assumed to be administered in combination with a weighted average androgen deprivation therapy comparator (consisting of luteinizing hormone-releasing hormone [LHRH] agonists, LHRH antagonists, and first-generation antiandrogens). Market share estimates were derived from interviews with physicians treating men with nmCRPC. The model includes grade 3-4 AEs, and the rates were obtained from clinical trial data. Costs were taken from publicly available sources and varied in a one-way sensitivity analysis. RESULTS: For a plan with 1 million lives, there were approximately 90 incident cases of nmCRPC (46 high risk) each year, with 332 (109 high risk) treatment-eligible cases by year 5. Darolutamide's market share increased from 3.6% in year 1 to 18% in year 5. Given the utilization of other agents, introducing darolutamide along with other targeted therapies was predicted to increase the total budget by $158,640 ($0.0132 per member per month [PMPM]) in year 1, which decreased over time to a cost savings of $149,240 ($0.0124 PMPM) by year 5. The scenario with darolutamide showed reduced AE costs each year. Similar results were observed for the high-risk nmCRPC population. CONCLUSIONS: Adding darolutamide to a U.S. payer formulary for the treatment of nmCRPC can result in a manageable increase in the budget that is partly offset by AE costs in the first 4 years, followed by a cost savings by year 5. DISCLOSURES: This study was conducted by RTI Health Solutions under the direction of Bayer U.S. and was funded by Bayer U.S., which was involved in the design of the study; collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the report for publication. Miles and Purser (and/or their institutions) are employees of RTI Health Solutions and received research funding from Bayer U.S. to develop the budget impact model. Appukkuttan and Farej are employees of Bayer U.S. Wen was an employee of Bayer U.S. at the time of the study. This study was presented as a poster at the AMCP Virtual Learning Event, April 20-24, 2020.